Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Russia Adds Medtech Regulatory Resources, Clarifies Tech Files & Instructions-For-Use Needs

Executive Summary

Russia's medtech regulatory agency Roszdravnadzor has received its share of criticism, but its performance has improved of late. New health ministry rules on technical file requirements have given the medtech industry additional cause for optimism.

You may also be interested in...



Mind 'Hidden' Regulatory Demands In Russia To Avoid Icy Chill Of Rejection, Expert Warns

Think of the Russian regulatory system as an iceberg – there is more to it than meets the eye, and medtech applicants must keep a keen look out to ensure they are compliant in every aspect of a submission. Russian market controls of already-launched products are also on the rise.

Flurry of Russian Medtech Regulatory System Proposals Keeps Manufacturers On Their Toes

Russian medtech industry expert Alexey Stepanov reports an uptick in regulatory activity nationally in the final trimester of 2016. The catalyst seems to be the impending launch of the system of harmonization of medical device regulation within the regional Eurasian Economic Union (EAEU).

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel